Nemolizumab ( DrugBank: Nemolizumab )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
51	Scleroderma	2

51. Scleroderma

---

Clinical trials : 523 /  Drugs : 608 - (DrugBank : 156) / Drug target genes : 114 - Drug target pathways : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05214794 (ClinicalTrials.gov)	February 14, 2022	17/1/2022	An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis	An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis	Systemic Sclerosis	Drug: nemolizumab	Maruho Co., Ltd.	NULL	Not yet recruiting	20 Years	70 Years	All	8	Phase 2	Japan
2	JPRN-jRCT2031210481	12/12/2021	12/12/2021	An Open-label, Phase 2 Study to Assess the Effecacy and Safety of Nemolizumab in Subjects with Systemic Sclerosis	An Open-label, Phase 2 Study to Assess the Effecacy and Safety of Nemolizumab in Subjects with Systemic Sclerosis	Systemic Sclerosis	Nemolizumab will be administered subcutaneously	Nishiura Tomoyuki	NULL	Pending	>= 20age old	<= 70age old	Both	8	Phase 2	Japan